[The Influence of COVID-19 Infection on the Mobilization and Collection of Autologous Peripheral Blood Stem Cells in Patients with Multiple Myeloma].

OBJECTIVE

To analyze the effect of COVID-19 infection on the mobilization and collection of autologous peripheral blood stem cells in patients with multiple myeloma.

METHODS

The general baseline data, treatment factors before mobilization collection, collection status, and treatment overview after collection of autologous peripheral blood stem cells at Beijing Chaoyang Hospital affiliated with Capital Medical University from January 1, 2020 to July 15, 2023 were analyzed.

RESULTS

269 patients underwent mobilization and collection of autologous peripheral blood stem cells. Among them, 32 cases with COVID-19 infection history (COVID-19 group) and 237 cases without COVID-19 infection history (non-COVID-19 group). In the COVID-19 group, 17 cases were treated with chemotherapy (etoposide)+G-CSF, and 15 cases were treated with plerixafor +G-CSF. In the non-COVID-19 group, 214 cases were treated with chemotherapy +G-CSF, 17 cases were treated with plerixafor +G-CSF, and 6 cases were treated with chemotherapy + plerixafor +G-CSF. The number of CD34 cells, collection success rate, and excellence rate in the COVID-19 group and the non-COVID-19 group were ［5.52 (0.94-26.87) 4.80 (0.53-37.20)］×10/kg ( =0.610), (93.8% 85.2%) ( =0.275), (62.5% 49.4%) ( =0.190), respectively. Among 113 patients mobilized with etoposide +G-CSF, the number of CD34 cells, success rate, and excellence rate collected from COVID-19 infection (17 cases) and non-COVID-19 infection (96 cases) were ［7.54 (2.66-26.87) 7.78 (2.26-37.20)］×10/kg ( =0.847), (100.0% 100.0%) (no value), (82.4% 86.5%) ( =0.655), respectively. Among 32 patients mobilized by plerixafor +G-CSF, the number of CD34 cells, success rate and excellence rate of COVID-19 infection (15 cases) and non-COVID-19 infection (17 cases) were ［3.82 (0.94-7.27) 4.11 (0.53-9.05)］×10/kg ( =0.821), (86.7% 88.2%) ( =0.893), (40.0% 35.3%) ( =0.784), respectively. In 32 patients with COVID-19 infection, the number of CD34 cells collected by etoposide +G-CSF (17 cases) and plerixafor +G-CSF (15 cases), as well as the success rate and excellence rate were ［7.54 (2.66-26.87) 3.82(0.94-7.27)］×10/kg ( =0.004), (100.0% 86.7%) ( =0.120), (82.4% 40.0%) ( =0.014), respectively. By 2023.7.31, 232 patients (86.2%, 232/269) had received transplantation, including 24 patients in the COVID-19 group and 208 patients in the non-COVID-19 group. The median number of CD34 cells infused in the two groups was ［3.67 (2.50-13.44) 3.11(1.12-19.89)］×10/kg ( =0.058), the median days of neutrophil engraftment ［11(9-13) 11(9-17)］ ( =0.674), the median days of platelet engraftment ［11(0-23), 12(0-43)］ ( =0.279), respectively.

CONCLUSION

The history of COVID-19 infection did not affect the PBSC mobilization, collection and transplantation of patients with myeloma. In patients with COVID-19 infection, the results of chemotherapy mobilization with etoposide seems to be better than that of plerixafor mobilization, but further research is needed to clarify.